Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.60 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9670503 | 0.89 | CYP1A2 (0.67) | CYP1A2FFAR1FFAR4PDPK1KDM4E | |
| SCHEMBL17592174 | 0.82 | GRIN2D (0.65) | GRIN2DGRIN2AGRIN2BGRIN2CTBXAS1 | |
| SCHEMBL30403190 | 0.81 | CYP1A2 (0.80) | CYP1A2FFAR1FFAR4PDPK1KEAP1 | |
| SCHEMBL12889161 | 0.81 | CYP1A2 (0.59) | CYP1A2FFAR1FFAR4PDPK1KDM4E | |
| SCHEMBL1217683 | 0.81 | CYP1A2 (0.80) | CYP1A2FFAR1FFAR4PDPK1KEAP1 | |
| SCHEMBL11468664 | 0.81 | PTGS1 (0.59) | GRIN2DGRIN2AGRIN2BGRIN2CTBXAS1 | |
| Adipic Acid SCHEMBL9893298 | 0.81 | KDM4E (0.53) | GRIN2DGRIN2AGRIN2BGRIN2CCYP1A2 | |
| Glutarate SCHEMBL29026188 | 0.81 | KDM4E (0.53) | GRIN2DGRIN2AGRIN2BGRIN2CCYP1A2 | |
| SCHEMBL12267750 | 0.81 | GRIN2D (0.58) | GRIN2DGRIN2AGRIN2BGRIN2CTBXAS1 | |
| SCHEMBL264975 | 0.81 | FFAR1 (0.65) | FFAR1FFAR4SRD5A2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CAGE PETER | 2009-01-08 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012125-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | GRIN2D 2933/4885GRIN2A 3499/4885GRIN2B 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.